In the current CLL study, the Vienna researchers could actually demonstrate that the advancement of a CMV vaccine is definitely focusing on the correct protein, namely glycoprotein B. During a short infection, the immune system forms defence elements against a variety of virus proteins, but if a further infection occurs it only remembers a small group of viral proteins, to which glycoprotein B belongs. Dormant CMV virus is constantly being fought in CLL patients Unlike other infections, instances of CMV among CLL patients are of lesser consequence. That is most likely due to the fact that the immune system effectively fights the dormant CMV virus whenever it is reawaken, training the system up thereby.He can talk about the importance of patients having a thorough evaluation under one roof with a close collaboration of multiple professionals. Elizabeth Poplin, MD, may be the co-director of the Gastrointestinal/Hepatobiliary Oncology System at CINJ and an associate professor of medicine at UMDNJ-Robert Timber Johnson Medical School. Dr. Poplin has clinical expertise in the administration of pancreatic tumor including novel and regular treatment options, including a fresh immune therapy trial that targets immediate injection in to the pancreas tumor. Edmund Lattime, PhD, is the deputy director at CINJ and associate director for training and education.